Researchers at the Case Western Reserve School of Medicine have found that when compared to seven other anti-diabetic drugs, semaglutide, a popular diabetes and weight-loss drug, may lower the risk of Alzheimer’s disease in people with type 2 diabetes (T2D).
This article was originally published on MedicalXpress.com